Details of the Drug Combination

General Information of Drug Combination (ID: DC6ALSO)

Drug Combination Name
Irinotecan Oxaliplatin
Indication
Disease Entry Status REF
Pancreatic Adenocarcinoma Phase 2 [1]
Component Drugs Irinotecan   DMP6SC2 Oxaliplatin   DMQNWRD
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Irinotecan
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [2]
Advanced cancer 2A00-2F9Z Approved [2]
Appendiceal neoplasm N.A. Approved [2]
Astrocytoma 2A00.0Y Approved [2]
Brain glioma N.A. Approved [2]
Colon adenocarcinoma N.A. Approved [2]
Colorectal cancer 2B91.Z Approved [3]
Endocrine gland neoplasm N.A. Approved [2]
Kidney neoplasm N.A. Approved [2]
Metastasis from malignant tumor of colon N.A. Approved [2]
Peritoneal neoplasm N.A. Approved [2]
Rectal adenocarcinoma 2B92 Approved [2]
Rectal neoplasm N.A. Approved [2]
Rectum mucinous adenocarcinoma N.A. Approved [2]
Adult glioblastoma N.A. Investigative [2]
Colon cancer 2B90.Z Investigative [2]
Colon mucinous adenocarcinoma N.A. Investigative [2]
Diarrhea ME05.1 Investigative [2]
Gastric cancer 2B72 Investigative [2]
Neuroblastoma 2D11.2 Investigative [2]
Irinotecan Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Modulator [14]
------------------------------------------------------------------------------------
Irinotecan Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [15]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [16]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [16]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [17]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [18]
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Irinotecan Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [20]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [21]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [22]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [23]
Carboxylesterase 1 (CES1) DEB30C5 EST1_HUMAN Metabolism [20]
Carboxylesterase 3 (CES3) DEMI4VE EST3_HUMAN Metabolism [24]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Metabolism [24]
Beta-glucuronidase (uidA) DE9RA0I BGLR_ECOLI Metabolism [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Irinotecan Interacts with 469 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Increases Expression [26]
Carboxylesterase 3 (CES3) OT00OP43 EST3_HUMAN Increases Hydrolysis [24]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Response To Substance [27]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases Response To Substance [27]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Expression [9]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Response To Substance [28]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Response To Substance [27]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Response To Substance [28]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Increases ADR [29]
Thiopurine S-methyltransferase (TPMT) OTFOX70W TPMT_HUMAN Increases Expression [9]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Decreases Activity [30]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [30]
Annexin A2 (ANXA2) OTFNS0CC ANXA2_HUMAN Increases Expression [31]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [31]
FXYD domain-containing ion transport regulator 3 (FXYD3) OT9PPRHE FXYD3_HUMAN Increases Expression [31]
B-cell CLL/lymphoma 9 protein (BCL9) OTRBIPR4 BCL9_HUMAN Increases Expression [8]
Chromodomain-helicase-DNA-binding protein 1 (CHD1) OT9R9G0H CHD1_HUMAN Decreases Expression [8]
Prostaglandin E synthase (PTGES) OTB7YQFU PTGES_HUMAN Increases Expression [8]
tRNA (TRDMT1) OTAYQ8ZF TRDMT_HUMAN Decreases Expression [8]
Guanine nucleotide exchange factor DBS (MCF2L) OTEURA8N MCF2L_HUMAN Decreases Expression [8]
Fanconi anemia group G protein (FANCG) OT7MC8TZ FANCG_HUMAN Increases Expression [8]
Monocarboxylate transporter 5 (SLC16A4) OT1YXBKC MOT5_HUMAN Decreases Expression [8]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [8]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Expression [8]
A-kinase anchor protein 10, mitochondrial (AKAP10) OTPNFTOU AKA10_HUMAN Decreases Expression [8]
Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1) OT80DZMT BUB1_HUMAN Decreases Expression [8]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [8]
G2/mitotic-specific cyclin-B2 (CCNB2) OTIEXTDK CCNB2_HUMAN Decreases Expression [8]
Heat shock 70 kDa protein 4L (HSPA4L) OT181WZB HS74L_HUMAN Decreases Expression [8]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Decreases Expression [8]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Increases Expression [8]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [8]
Lactotransferrin (LTF) OT8JWCZ0 TRFL_HUMAN Decreases Expression [8]
Histidine-rich glycoprotein (HRG) OTPLUFOG HRG_HUMAN Increases Expression [8]
Thy-1 membrane glycoprotein (THY1) OTVONVTB THY1_HUMAN Increases Expression [8]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Increases Expression [8]
Myeloperoxidase (MPO) OTOOXLIN PERM_HUMAN Decreases Expression [8]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [8]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [8]
Integrin alpha-V (ITGAV) OTAM7JTR ITAV_HUMAN Decreases Expression [8]
Annexin A6 (ANXA6) OT9KIQ0Y ANXA6_HUMAN Increases Expression [8]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [8]
Sulfotransferase 1A3 (SULT1A4) OTHJ8WWV ST1A3_HUMAN Increases Expression [8]
Serine/threonine-protein kinase A-Raf (ARAF) OTZJ0FNO ARAF_HUMAN Increases Expression [8]
DNA topoisomerase 2-alpha (TOP2A) OT6LPS08 TOP2A_HUMAN Decreases Expression [8]
Collagen alpha-1(VI) chain (COL6A1) OTYKSCOB CO6A1_HUMAN Increases Expression [8]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Decreases Expression [8]
Nidogen-1 (NID1) OTKLBLS6 NID1_HUMAN Increases Expression [8]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Increases Expression [8]
Protein C-ets-2 (ETS2) OTPVHOZ7 ETS2_HUMAN Increases Expression [8]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [8]
Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform (PPP3CB) OTEGNEHW PP2BB_HUMAN Decreases Expression [8]
SH2/SH3 adapter protein NCK1 (NCK1) OTKYZ4OP NCK1_HUMAN Decreases Expression [8]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [8]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [8]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [8]
Interferon-induced GTP-binding protein Mx2 (MX2) OT05NF37 MX2_HUMAN Decreases Expression [8]
Integrin alpha-X (ITGAX) OTOGIMHE ITAX_HUMAN Increases Expression [8]
Myelin and lymphocyte protein (MAL) OTBM30SW MAL_HUMAN Increases Expression [8]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Increases Expression [8]
5-aminolevulinate synthase, erythroid-specific, mitochondrial (ALAS2) OTJXOUCL HEM0_HUMAN Increases Expression [8]
Receptor-type tyrosine-protein phosphatase delta (PTPRD) OTZPJ3GX PTPRD_HUMAN Increases Expression [8]
Trans-acting T-cell-specific transcription factor GATA-3 (GATA3) OTGP7D5Y GATA3_HUMAN Decreases Expression [8]
Adenomatous polyposis coli protein (APC) OTKV0TIK APC_HUMAN Decreases Expression [8]
Retinoblastoma-like protein 1 (RBL1) OTDEBFYC RBL1_HUMAN Decreases Expression [8]
AT-rich interactive domain-containing protein 4A (ARID4A) OT1XKBZ0 ARI4A_HUMAN Decreases Expression [8]
M-phase inducer phosphatase 2 (CDC25B) OT12MSRY MPIP2_HUMAN Decreases Expression [8]
Syndecan-4 (SDC4) OTKUVUGZ SDC4_HUMAN Increases Expression [8]
C-C chemokine receptor type 1 (CCR1) OT4FC783 CCR1_HUMAN Increases Expression [8]
G-protein coupled receptor 183 (GPR183) OTRILX7G GP183_HUMAN Increases Expression [8]
CD70 antigen (CD70) OTHB2AL1 CD70_HUMAN Increases Expression [8]
T-lymphocyte activation antigen CD80 (CD80) OTJBLUQE CD80_HUMAN Increases Expression [8]
Dual specificity protein kinase TTK (TTK) OTBY1Z5H TTK_HUMAN Decreases Expression [8]
DNA replication licensing factor MCM4 (MCM4) OT19PNNG MCM4_HUMAN Decreases Expression [8]
Replication factor C subunit 3 (RFC3) OT1MS7AO RFC3_HUMAN Decreases Expression [8]
Cyclin-F (CCNF) OTJFVU43 CCNF_HUMAN Decreases Expression [8]
Transcription factor ETV6 (ETV6) OTCZMG61 ETV6_HUMAN Decreases Expression [8]
DNA mismatch repair protein Msh2 (MSH2) OT10H1AB MSH2_HUMAN Decreases Expression [8]
Hydroxycarboxylic acid receptor 3 (HCAR3) OTJBHLX0 HCAR3_HUMAN Increases Expression [8]
Centromere protein F (CENPF) OT7AG0SW CENPF_HUMAN Decreases Expression [8]
Caspase-4 (CASP4) OTVQTV1L CASP4_HUMAN Decreases Expression [8]
5-formyltetrahydrofolate cyclo-ligase (MTHFS) OTZ39JNR MTHFS_HUMAN Decreases Expression [8]
Protein Tob1 (TOB1) OTNW949D TOB1_HUMAN Increases Expression [8]
C-C chemokine receptor type 6 (CCR6) OT61JMYX CCR6_HUMAN Decreases Expression [8]
Serine/threonine-protein kinase Nek2 (NEK2) OT1H27HO NEK2_HUMAN Decreases Expression [8]
Serine/threonine-protein kinase PLK1 (PLK1) OTRZX45T PLK1_HUMAN Decreases Expression [8]
Protein FosB (FOSB) OTW6C05J FOSB_HUMAN Increases Expression [8]
UV excision repair protein RAD23 homolog B (RAD23B) OT0PGOG3 RD23B_HUMAN Decreases Expression [8]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Increases Expression [8]
Neutrophil defensin 1 (DEFA1) OT5N1B9B DEF1_HUMAN Decreases Expression [8]
Ras-related C3 botulinum toxin substrate 3 (RAC3) OT2RE7A7 RAC3_HUMAN Increases Expression [8]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Decreases Expression [8]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [8]
Runt-related transcription factor 1 (RUNX1) OTU7J84H RUNX1_HUMAN Decreases Expression [8]
Transcription factor Spi-B (SPIB) OTO4YKYI SPIB_HUMAN Increases Expression [8]
Myocyte-specific enhancer factor 2B (MEF2B) OT880SE6 MEF2B_HUMAN Increases Expression [8]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Decreases Expression [8]
Dual specificity protein phosphatase 2 (DUSP2) OTH54FMR DUS2_HUMAN Increases Expression [8]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B) OTOA8WU2 PDE4B_HUMAN Decreases Expression [8]
Regulator of G-protein signaling 1 (RGS1) OTGXJYMG RGS1_HUMAN Increases Expression [8]
Dystrophia myotonica WD repeat-containing protein (DMWD) OT0CBZ6F DMWD_HUMAN Increases Expression [8]
Histone acetyltransferase p300 (EP300) OTL8QJDX EP300_HUMAN Decreases Expression [8]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Expression [8]
Tyrosine-protein phosphatase non-receptor type 13 (PTPN13) OTESFZSO PTN13_HUMAN Decreases Expression [8]
Rho GTPase-activating protein 5 (ARHGAP5) OTOQELUN RHG05_HUMAN Decreases Expression [8]
MAL-like protein (MALL) OTKGZ89D MALL_HUMAN Increases Expression [8]
TNF receptor-associated factor 1 (TRAF1) OTTLM5RU TRAF1_HUMAN Decreases Expression [8]
Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1) OTXNGZCG MD2L1_HUMAN Decreases Expression [8]
Cyclin-dependent kinase 5 activator 2 (CDK5R2) OTNUTLPU CD5R2_HUMAN Increases Expression [8]
Centromere protein R (ITGB3BP) OT6Q7GR3 CENPR_HUMAN Decreases Expression [8]
Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) OTPLXCDN DYR1A_HUMAN Decreases Expression [8]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Increases Expression [8]
Krueppel-like factor 9 (KLF9) OTBFEJRQ KLF9_HUMAN Increases Expression [8]
Cyclin-dependent kinase 13 (CDK13) OT3P7JF1 CDK13_HUMAN Decreases Expression [8]
Protein Tob2 (TOB2) OTEEHL60 TOB2_HUMAN Increases Expression [8]
Serine/threonine-protein kinase 38 (STK38) OTKMYCYR STK38_HUMAN Increases Expression [8]
Retinoblastoma-binding protein 5 (RBBP5) OT12W2MK RBBP5_HUMAN Decreases Expression [8]
Receptor tyrosine-protein kinase erbB-4 (ERBB4) OT9L6C41 ERBB4_HUMAN Increases Expression [8]
Na(+)/H(+) exchange regulatory cofactor NHE-RF2 (NHERF2) OTRHB9SR NHRF2_HUMAN Increases Expression [8]
Tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) OTBOSJHO TRADD_HUMAN Increases Expression [8]
Nuclear receptor coactivator 1 (NCOA1) OTLIUJQD NCOA1_HUMAN Increases Expression [8]
Tubulin-specific chaperone C (TBCC) OTBF0X8R TBCC_HUMAN Increases Expression [8]
Cyclin-dependent kinase inhibitor 3 (CDKN3) OTBE3H07 CDKN3_HUMAN Decreases Expression [8]
Receptor-type tyrosine-protein phosphatase-like N (PTPRN) OTAP7NOL PTPRN_HUMAN Increases Expression [8]
B-cell CLL/lymphoma 7 protein family member A (BCL7A) OTYFUJTP BCL7A_HUMAN Increases Expression [8]
Transmembrane protein 41B (TMEM41B) OTW0B0KS TM41B_HUMAN Decreases Expression [8]
Transcription initiation factor TFIID subunit 2 (TAF2) OTTIGJ9M TAF2_HUMAN Decreases Expression [8]
DNA cross-link repair 1A protein (DCLRE1A) OT68PVSD DCR1A_HUMAN Decreases Expression [8]
C-myc promoter-binding protein (DENND4A) OT8FFZ29 MYCPP_HUMAN Decreases Expression [8]
COMM domain-containing protein 6 (COMMD6) OTRZQJFW COMD6_HUMAN Increases Expression [8]
Bone morphogenetic protein 8A (BMP8A) OT1997IN BMP8A_HUMAN Increases Expression [8]
Pleckstrin homology domain-containing family H member 3 (PLEKHH3) OTREOQBO PKHH3_HUMAN Increases Expression [8]
DNA damage-binding protein 2 (DDB2) OTO8HVVB DDB2_HUMAN Increases Expression [8]
Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) OTMDVWPS DYRK2_HUMAN Decreases Expression [8]
Histone H2A type 1-C (H2AC6) OTF3YK7V H2A1C_HUMAN Decreases Expression [8]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Decreases Expression [8]
Sorting nexin-18 (SNX18) OT68KT3X SNX18_HUMAN Decreases Expression [8]
Oncostatin-M-specific receptor subunit beta (OSMR) OTORWHPL OSMR_HUMAN Increases Expression [8]
Mitogen-activated protein kinase kinase kinase 5 (MAP3K5) OTQR6ENW M3K5_HUMAN Decreases Expression [8]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [8]
Ubiquitin-like-conjugating enzyme ATG10 (ATG10) OTVRPC5X ATG10_HUMAN Decreases Expression [8]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [8]
E3 ubiquitin-protein ligase Topors (TOPORS) OT1ERFFQ TOPRS_HUMAN Decreases Expression [8]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases Expression [8]
Gamma-adducin (ADD3) OTDRSHAZ ADDG_HUMAN Decreases Expression [8]
Targeting protein for Xklp2 (TPX2) OTWLJYH0 TPX2_HUMAN Decreases Expression [8]
Protocadherin gamma-C3 (PCDHGC3) OTDXTUMI PCDGK_HUMAN Increases Expression [8]
Tyrosine-protein phosphatase non-receptor type 22 (PTPN22) OTDCNTC3 PTN22_HUMAN Increases Expression [8]
Structural maintenance of chromosomes flexible hinge domain-containing protein 1 (SMCHD1) OTBV52DR SMHD1_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Increases Expression [9]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Increases Expression [9]
Krev interaction trapped protein 1 (KRIT1) OT58AP1I KRIT1_HUMAN Decreases Expression [9]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Decreases Expression [9]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Increases Expression [9]
Heterogeneous nuclear ribonucleoprotein D-like (HNRNPDL) OTB3BFCV HNRDL_HUMAN Decreases Expression [9]
Centrosomal protein of 290 kDa (CEP290) OTVN52VH CE290_HUMAN Decreases Expression [9]
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A (ANKRD28) OTRBREQ9 ANR28_HUMAN Decreases Expression [9]
FYN-binding protein 1 (FYB1) OT6345CH FYB1_HUMAN Decreases Expression [9]
Protein phosphatase 1D (PPM1D) OT8NLZ9D PPM1D_HUMAN Increases Expression [9]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Decreases Expression [9]
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Increases Expression [9]
Density-regulated protein (DENR) OTXP9HOY DENR_HUMAN Decreases Expression [9]
E3 ubiquitin-protein ligase MARCHF6 (MARCHF6) OTBTA03N MARH6_HUMAN Increases Expression [9]
Oligophrenin-1 (OPHN1) OTDURZAV OPHN1_HUMAN Increases Expression [9]
NEDD4-binding protein 1 (N4BP1) OTN2TL6N N4BP1_HUMAN Decreases Expression [9]
Ankyrin repeat domain-containing protein 17 (ANKRD17) OTQ3DYEP ANR17_HUMAN Decreases Expression [9]
Nuclear receptor corepressor 1 (NCOR1) OT04XNOU NCOR1_HUMAN Decreases Expression [9]
Death effector domain-containing protein (DEDD) OTIL349E DEDD_HUMAN Decreases Expression [9]
Glutaredoxin-3 (GLRX3) OTUPAU1N GLRX3_HUMAN Affects Expression [9]
Tubulin polymerization-promoting protein (TPPP) OTCFMSUF TPPP_HUMAN Increases Expression [9]
Protein transport protein Sec31A (SEC31A) OT2U42AC SC31A_HUMAN Decreases Expression [9]
SR-related and CTD-associated factor 4 (SCAF4) OTFGHB1E SCAF4_HUMAN Decreases Expression [9]
Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) OT9QIHEQ RECK_HUMAN Increases Expression [9]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Decreases Expression [9]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [9]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Decreases Expression [9]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) OTRGGIFP DRB1_HUMAN Increases Expression [9]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Decreases Expression [9]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [9]
Albumin (ALB) OTVMM513 ALBU_HUMAN Decreases Expression [9]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Increases Expression [9]
Alpha-enolase (ENO1) OTB1KWJS ENOA_HUMAN Decreases Expression [9]
Transcription factor Sp1 (SP1) OTISPT4X SP1_HUMAN Decreases Expression [9]
Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) OTIRPN6B ROA1_HUMAN Decreases Expression [9]
U2 small nuclear ribonucleoprotein A' (SNRPA1) OTWJZFAP RU2A_HUMAN Decreases Expression [9]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Increases Expression [9]
Chorionic somatomammotropin hormone 2 (CSH2) OTW8JVAN CSH2_HUMAN Decreases Expression [9]
Tissue factor pathway inhibitor (TFPI) OTA0FX16 TFPI1_HUMAN Decreases Expression [9]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Expression [9]
Interferon-induced transmembrane protein 1 (IFITM1) OTECO1G8 IFM1_HUMAN Increases Expression [9]
HLA class II histocompatibility antigen, DR beta 4 chain (HLA-DRB4) OTNXIHQU DRB4_HUMAN Increases Expression [9]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Decreases Expression [9]
Arylsulfatase B (ARSB) OTTYDDNU ARSB_HUMAN Decreases Expression [9]
Carboxypeptidase E (CPE) OTXNTV79 CBPE_HUMAN Increases Expression [9]
Integrin alpha-2 (ITGA2) OTPFL017 ITA2_HUMAN Increases Expression [9]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Affects Expression [9]
Peptidyl-glycine alpha-amidating monooxygenase (PAM) OTX8HV5B AMD_HUMAN Decreases Expression [9]
Glutathione hydrolase 1 proenzyme (GGT1) OTYDA1Z7 GGT1_HUMAN Decreases Expression [9]
Ras GTPase-activating protein 1 (RASA1) OTZJ3LP4 RASA1_HUMAN Decreases Expression [9]
Synaptotagmin-1 (SYT1) OTVTPOI6 SYT1_HUMAN Decreases Expression [9]
Receptor-type tyrosine-protein phosphatase gamma (PTPRG) OT9N2WOF PTPRG_HUMAN Decreases Expression [9]
Paired box protein Pax-7 (PAX7) OTDMQRPO PAX7_HUMAN Decreases Expression [9]
Annexin A13 (ANXA13) OTM33P73 ANX13_HUMAN Decreases Expression [9]
Lens fiber major intrinsic protein (MIP) OTEBLU3E MIP_HUMAN Decreases Expression [9]
Fibroblast growth factor 9 (FGF9) OT2SKDGM FGF9_HUMAN Decreases Expression [9]
Glycerol kinase (GK) OTK2YRA0 GLPK_HUMAN Decreases Expression [9]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Increases Expression [9]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Decreases Expression [9]
Large ribosomal subunit protein uL4 (RPL4) OTTYJB0X RL4_HUMAN Decreases Expression [9]
T-complex protein 1 subunit zeta (CCT6A) OTCYWL5F TCPZ_HUMAN Decreases Expression [9]
Reduced folate transporter (SLC19A1) OTWB0BTO S19A1_HUMAN Decreases Expression [9]
Matrin-3 (MATR3) OTESJ5S7 MATR3_HUMAN Decreases Expression [9]
Transcriptional regulator ATRX (ATRX) OT77RSQW ATRX_HUMAN Decreases Expression [9]
Vesicle-fusing ATPase (NSF) OTKRJ2ZT NSF_HUMAN Decreases Expression [9]
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Decreases Expression [9]
Nuclear pore complex protein Nup153 (NUP153) OTCAS0AR NU153_HUMAN Decreases Expression [9]
Gastrotropin (FABP6) OTIRQWLW FABP6_HUMAN Increases Expression [9]
Host cell factor 1 (HCFC1) OT0UCK62 HCFC1_HUMAN Decreases Expression [9]
Collagen alpha-4(IV) chain (COL4A4) OT9G0MCT CO4A4_HUMAN Decreases Expression [9]
Coatomer subunit alpha (COPA) OTZ1DTXU COPA_HUMAN Increases Expression [9]
Cadherin-4 (CDH4) OT8LH3HN CADH4_HUMAN Decreases Expression [9]
C-terminal-binding protein 2 (CTBP2) OTGZGT87 CTBP2_HUMAN Decreases Expression [9]
ADP-ribosylation factor-like protein 4C (ARL4C) OTQ3QNNU ARL4C_HUMAN Increases Expression [9]
Epiplakin (EPPK1) OT7BAU8C EPIPL_HUMAN Increases Expression [9]
Lysyl oxidase homolog 3 (LOXL3) OTLLY1QI LOXL3_HUMAN Decreases Expression [9]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Decreases Expression [9]
AP-2 complex subunit beta (AP2B1) OTL6LZJ4 AP2B1_HUMAN Decreases Expression [9]
Hemoglobin subunit gamma-1 (HBG1) OTVL4NSU HBG1_HUMAN Decreases Expression [9]
Mothers against decapentaplegic homolog 3 (SMAD3) OTNA96MR SMAD3_HUMAN Decreases Expression [9]
ADP-ribosylation factor 1 (ARF1) OT5C4C3L ARF1_HUMAN Decreases Expression [9]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Affects Expression [9]
Clathrin heavy chain 1 (CLTC) OTBFASMA CLH1_HUMAN Decreases Expression [9]
Centromere-associated protein E (CENPE) OTQ7AP04 CENPE_HUMAN Decreases Expression [9]
Paired box protein Pax-5 (PAX5) OTYBJJWX PAX5_HUMAN Decreases Expression [9]
Dystonin (DST) OTHZBM4X DYST_HUMAN Decreases Expression [9]
Focal adhesion kinase 1 (PTK2) OT3Q1JDY FAK1_HUMAN Decreases Expression [9]
Recombining binding protein suppressor of hairless (RBPJ) OTD7CUG0 SUH_HUMAN Decreases Expression [9]
KH domain-containing, RNA-binding, signal transduction-associated protein 1 (KHDRBS1) OT5GO2PL KHDR1_HUMAN Decreases Expression [9]
Protein phosphatase 3 catalytic subunit alpha (PPP3CA) OT58PUEN PP2BA_HUMAN Decreases Expression [9]
Leukocyte surface antigen CD47 (CD47) OTLDZ0KZ CD47_HUMAN Increases Expression [9]
Transmembrane protein 267 (TMEM267) OTEAAVK7 TM267_HUMAN Decreases Expression [9]
Proline-rich nuclear receptor coactivator 1 (PNRC1) OTQMLEE1 PNRC1_HUMAN Increases Expression [9]
Alpha-globin transcription factor CP2 (TFCP2) OTA246TE TFCP2_HUMAN Decreases Expression [9]
Disks large homolog 1 (DLG1) OTCRZYWT DLG1_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase 4 (STK4) OTBRYNNH STK4_HUMAN Decreases Expression [9]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Decreases Expression [9]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Decreases Expression [9]
BMP and activin membrane-bound inhibitor homolog (BAMBI) OTCEJ8W5 BAMBI_HUMAN Increases Expression [9]
Dynactin subunit 2 (DCTN2) OTMB4IXD DCTN2_HUMAN Increases Expression [9]
Cullin-4A (CUL4A) OTTBV70J CUL4A_HUMAN Decreases Expression [9]
Heterogeneous nuclear ribonucleoprotein D0 (HNRNPD) OT5UO1FA HNRPD_HUMAN Decreases Expression [9]
Guanine nucleotide-binding protein subunit alpha-13 (GNA13) OTVDL515 GNA13_HUMAN Increases Expression [9]
Disco-interacting protein 2 homolog A (DIP2A) OTXPTR8R DIP2A_HUMAN Decreases Expression [9]
Uncharacterized protein KIAA0040 (KIAA0040) OT27EBY3 K0040_HUMAN Increases Expression [9]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Decreases Expression [9]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Expression [9]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Increases Expression [9]
MICOS complex subunit MIC60 (IMMT) OTBDSLE7 MIC60_HUMAN Affects Expression [9]
WD40 repeat-containing protein SMU1 (SMU1) OTLCSLGL SMU1_HUMAN Decreases Expression [9]
Neuroblastoma breakpoint family member 1 (NBPF1) OTAZ55UQ NBPF1_HUMAN Decreases Expression [9]
Cell adhesion molecule-related/down-regulated by oncogenes (CDON) OT81X593 CDON_HUMAN Decreases Expression [9]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Decreases Expression [9]
Shugoshin 2 (SGO2) OTNGJDS8 SGO2_HUMAN Decreases Expression [9]
PAN2-PAN3 deadenylation complex subunit PAN3 (PAN3) OTYBA69S PAN3_HUMAN Decreases Expression [9]
Sterile alpha motif domain-containing protein 9 (SAMD9) OTDG48P0 SAMD9_HUMAN Increases Expression [9]
Serine/threonine-protein phosphatase 4 regulatory subunit 3B (PPP4R3B) OT1VTUL9 P4R3B_HUMAN Decreases Expression [9]
Acyl-coenzyme A thioesterase THEM4 (THEM4) OTSIZU8Y THEM4_HUMAN Decreases Expression [9]
MAGUK p55 subfamily member 7 (MPP7) OT3G3HTZ MPP7_HUMAN Increases Expression [9]
DDB1- and CUL4-associated factor 8 (DCAF8) OT3VFSLG DCAF8_HUMAN Decreases Expression [9]
Collagen alpha-1(XIII) chain (COL13A1) OTM9IM6J CODA1_HUMAN Increases Expression [9]
Probable E3 ubiquitin-protein ligase HECTD2 (HECTD2) OTDIBGQV HECD2_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase MRCK alpha (CDC42BPA) OTCPFOSA MRCKA_HUMAN Decreases Expression [9]
Rho GTPase-activating protein SYDE2 (SYDE2) OTOEIXSM SYDE2_HUMAN Increases Expression [9]
Deubiquitinase MYSM1 (MYSM1) OTO73N00 MYSM1_HUMAN Decreases Expression [9]
AT-rich interactive domain-containing protein 2 (ARID2) OTIRJXWM ARID2_HUMAN Decreases Expression [9]
Glucose 1,6-bisphosphate synthase (PGM2L1) OTSBNRT5 PGM2L_HUMAN Increases Expression [9]
UPF0547 protein C16orf87 (C16ORF87) OT658H5A CP087_HUMAN Decreases Expression [9]
Kelch-like protein 24 (KLHL24) OTWZSX5C KLH24_HUMAN Increases Expression [9]
Monofunctional C1-tetrahydrofolate synthase, mitochondrial (MTHFD1L) OTV01EFP C1TM_HUMAN Decreases Expression [9]
Rho-related GTP-binding protein RhoU (RHOU) OTERIAD4 RHOU_HUMAN Increases Expression [9]
Protein ABHD13 (ABHD13) OTF2E8M6 ABHDD_HUMAN Decreases Expression [9]
G2/M phase-specific E3 ubiquitin-protein ligase (G2E3) OT06BFRQ G2E3_HUMAN Decreases Expression [9]
Diphthine--ammonia ligase (DPH6) OTOJ7BXR DPH6_HUMAN Decreases Expression [9]
Pogo transposable element with ZNF domain (POGZ) OT4CYWC1 POGZ_HUMAN Decreases Expression [9]
FERM domain-containing protein 5 (FRMD5) OTC73XJK FRMD5_HUMAN Decreases Expression [9]
Phosphatidylinositol-glycan biosynthesis class W protein (PIGW) OTT9SMTF PIGW_HUMAN Decreases Expression [9]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Increases Expression [9]
Dihydrofolate reductase 2, mitochondrial (DHFR2) OTPHUWEY DYR2_HUMAN Decreases Expression [9]
ELKS/Rab6-interacting/CAST family member 1 (ERC1) OTYBGGNO RB6I2_HUMAN Decreases Expression [9]
Armadillo repeat-containing protein 8 (ARMC8) OTNAXGM7 ARMC8_HUMAN Decreases Expression [9]
Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3) OTNJX38T M4K3_HUMAN Decreases Expression [9]
Protein FAM219A (FAM219A) OTAFZHY9 F219A_HUMAN Decreases Expression [9]
Homeobox protein Mohawk (MKX) OT7H7Z50 MKX_HUMAN Decreases Expression [9]
Threonine synthase-like 1 (THNSL1) OTQNFH3E THNS1_HUMAN Decreases Expression [9]
Porimin (TMEM123) OTDMVZD6 PORIM_HUMAN Decreases Expression [9]
Rho guanine nucleotide exchange factor 39 (ARHGEF39) OT9UKTQ5 ARG39_HUMAN Decreases Expression [9]
Type 2 DNA topoisomerase 6 subunit B-like (TOP6BL) OTCYPUNK TO6BL_HUMAN Increases Expression [9]
Protein SCAI (SCAI) OTAK3TMO SCAI_HUMAN Decreases Expression [9]
Diacylglycerol lipase-beta (DAGLB) OT1S9869 DGLB_HUMAN Decreases Expression [9]
Regulator of G-protein signaling 22 (RGS22) OTCTFGW6 RGS22_HUMAN Decreases Expression [9]
Phospholipase DDHD1 (DDHD1) OTWTHOWK DDHD1_HUMAN Decreases Expression [9]
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) OTCV7AGV PCAT1_HUMAN Decreases Expression [9]
Biorientation of chromosomes in cell division protein 1-like 1 (BOD1L1) OTTD5FJ8 BD1L1_HUMAN Decreases Expression [9]
Atlastin-2 (ATL2) OT93AUOO ATLA2_HUMAN Increases Expression [9]
Centrosomal protein of 192 kDa (CEP192) OTBLFV7T CE192_HUMAN Decreases Expression [9]
DEP domain-containing protein 1B (DEPDC1B) OTMVFOT1 DEP1B_HUMAN Decreases Expression [9]
Pleckstrin homology-like domain family A member 1 (PHLDA1) OTFTWMIQ PHLA1_HUMAN Decreases Expression [9]
Microprocessor complex subunit DGCR8 (DGCR8) OT62LXE4 DGCR8_HUMAN Decreases Expression [9]
Tribbles homolog 2 (TRIB2) OTHSX3MX TRIB2_HUMAN Affects Expression [9]
Protein FAM3C (FAM3C) OTBR6U9G FAM3C_HUMAN Decreases Expression [9]
CREB-binding protein (CREBBP) OTPA4QGM CBP_HUMAN Decreases Expression [9]
Histone acetyltransferase KAT2B (KAT2B) OTWQITWK KAT2B_HUMAN Increases Expression [9]
Homeobox protein DLX-4 (DLX4) OTLWVCN4 DLX4_HUMAN Increases Expression [9]
Protein tyrosine phosphatase type IVA 1 (PTP4A1) OTK0NFXJ TP4A1_HUMAN Decreases Expression [9]
Tumor protein p53-inducible nuclear protein 1 (TP53INP1) OT2363Z9 T53I1_HUMAN Increases Expression [9]
Exocyst complex component 4 (EXOC4) OT5EWXAN EXOC4_HUMAN Decreases Expression [9]
RalBP1-associated Eps domain-containing protein 1 (REPS1) OTX4ERRK REPS1_HUMAN Decreases Expression [9]
Protein LTV1 homolog (LTV1) OTZILJDI LTV1_HUMAN Decreases Expression [9]
PDZ and LIM domain protein 5 (PDLIM5) OTLQVV22 PDLI5_HUMAN Decreases Expression [9]
DISP complex protein LRCH3 (LRCH3) OTDLBLMU LRCH3_HUMAN Decreases Expression [9]
Rho GTPase-activating protein 7 (DLC1) OTP8LMCR RHG07_HUMAN Decreases Expression [9]
Tribbles homolog 1 (TRIB1) OTPEO17G TRIB1_HUMAN Increases Expression [9]
Mitochondrial inner membrane protease subunit 2 (IMMP2L) OT9WGAFD IMP2L_HUMAN Decreases Expression [9]
Transcription factor 12 (TCF12) OTZVONNU HTF4_HUMAN Decreases Expression [9]
ATP synthase subunit s, mitochondrial (DMAC2L) OT2OQ1UD ATP5S_HUMAN Decreases Expression [9]
Semaphorin-3C (SEMA3C) OTEGUY7F SEM3C_HUMAN Increases Expression [9]
2-(3-amino-3-carboxypropyl)histidine synthase subunit 2 (DPH2) OT9P91XR DPH2_HUMAN Decreases Expression [9]
Mitochondrial 2-oxodicarboxylate carrier (SLC25A21) OTB78IF4 ODC_HUMAN Decreases Expression [9]
Deubiquitinase DESI2 (DESI2) OTHUOKOC DESI2_HUMAN Decreases Expression [9]
Acireductone dioxygenase (ADI1) OT8IOD03 MTND_HUMAN Decreases Expression [9]
Protein C1orf43 (C1ORF43) OTT9CVZR CA043_HUMAN Decreases Expression [9]
RNA-binding protein 24 (RBM24) OTQI1AR1 RBM24_HUMAN Increases Expression [9]
Nucleolar and spindle-associated protein 1 (NUSAP1) OT85HIJ5 NUSAP_HUMAN Decreases Expression [9]
E3 ubiquitin-protein ligase TRIM9 (TRIM9) OTKYG33W TRIM9_HUMAN Increases Expression [9]
E3 ubiquitin-protein ligase TRIM4 (TRIM4) OTLKQNKQ TRIM4_HUMAN Increases Expression [9]
Histone-lysine N-methyltransferase SETD5 (SETD5) OTRPAVEO SETD5_HUMAN Decreases Expression [9]
Alpha-ketoglutarate-dependent dioxygenase FTO (FTO) OTXML85Y FTO_HUMAN Decreases Expression [9]
Centrosomal protein of 295 kDa (CEP295) OTVTTXRO CE295_HUMAN Decreases Expression [9]
Sentrin-specific protease 6 (SENP6) OT05LLF4 SENP6_HUMAN Decreases Expression [9]
Cytochrome c oxidase assembly factor 1 homolog (COA1) OTHSX40F COA1_HUMAN Decreases Expression [9]
Disintegrin and metalloproteinase domain-containing protein 19 (ADAM19) OTH88TXU ADA19_HUMAN Increases Expression [9]
Pterin-4-alpha-carbinolamine dehydratase 2 (PCBD2) OTXV0ZD0 PHS2_HUMAN Decreases Expression [9]
Metal transporter CNNM2 (CNNM2) OTZHO8WU CNNM2_HUMAN Increases Expression [9]
Pleckstrin homology domain-containing family A member 5 (PLEKHA5) OT2MNW8T PKHA5_HUMAN Decreases Expression [9]
Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial (MCCC2) OTQDHSMI MCCB_HUMAN Decreases Expression [9]
E3 ubiquitin-protein ligase SMURF1 (SMURF1) OT5UIZR8 SMUF1_HUMAN Affects Expression [9]
Large ribosomal subunit protein mL65 (MRPS30) OTDXIAGG RT30_HUMAN Decreases Expression [9]
Transcription factor 7-like 2 (TCF7L2) OTVWPZ8B TF7L2_HUMAN Decreases Expression [9]
Muscleblind-like protein 1 (MBNL1) OTOV7J85 MBNL1_HUMAN Decreases Expression [9]
Lymphoid-specific helicase (HELLS) OTVVV668 HELLS_HUMAN Decreases Expression [9]
Phenylalanine--tRNA ligase beta subunit (FARSB) OT8N9TT5 SYFB_HUMAN Decreases Expression [9]
Midasin (MDN1) OTNBSPTW MDN1_HUMAN Affects Expression [9]
tRNA:m(4)X modification enzyme TRM13 homolog (TRMT13) OT2H0MCE TRM13_HUMAN Decreases Expression [9]
E3 ubiquitin-protein ligase RLIM (RLIM) OTEBRNHJ RNF12_HUMAN Decreases Expression [9]
G patch domain-containing protein 2-like (GPATCH2L) OTETUZ64 GPT2L_HUMAN Decreases Expression [9]
Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG1) OTFOJUIQ PHAG1_HUMAN Increases Expression [9]
Huntingtin-interacting protein K (HYPK) OTRWRVWN HYPK_HUMAN Affects Expression [9]
Inhibitor of growth protein 3 (ING3) OTDIJXFP ING3_HUMAN Decreases Expression [9]
Rho guanine nucleotide exchange factor 12 (ARHGEF12) OTM2D3LT ARHGC_HUMAN Decreases Expression [9]
Cysteine-rich motor neuron 1 protein (CRIM1) OTTZNV6Y CRIM1_HUMAN Decreases Expression [9]
Voltage-dependent T-type calcium channel subunit alpha-1I (CACNA1I) OTRH8X8A CAC1I_HUMAN Decreases Expression [9]
eIF-2-alpha kinase GCN2 (EIF2AK4) OTLE1JY8 E2AK4_HUMAN Affects Expression [9]
DNA polymerase kappa (POLK) OTKZ38JH POLK_HUMAN Decreases Expression [9]
Mediator of RNA polymerase II transcription subunit 13 (MED13) OTP5LEJE MED13_HUMAN Decreases Expression [9]
Jupiter microtubule associated homolog 1 (JPT1) OT6CRZEU JUPI1_HUMAN Decreases Expression [9]
BTB/POZ domain-containing protein 3 (BTBD3) OTZ607YT BTBD3_HUMAN Decreases Expression [9]
Thyroid hormone receptor-associated protein 3 (THRAP3) OTG25JOG TR150_HUMAN Decreases Expression [9]
rRNA-processing protein FCF1 homolog (FCF1) OTTI9M2D FCF1_HUMAN Affects Expression [9]
Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 (SAMHD1) OTBCIBC7 SAMH1_HUMAN Affects Expression [9]
Heparan sulfate glucosamine 3-O-sulfotransferase 3B1 (HS3ST3B1) OTK53GUD HS3SB_HUMAN Increases Expression [9]
Calcineurin-binding protein cabin-1 (CABIN1) OT4G5CIK CABIN_HUMAN Decreases Expression [9]
Proton-coupled zinc antiporter SLC30A1 (SLC30A1) OTY8J0S4 ZNT1_HUMAN Decreases Expression [9]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Increases Phosphorylation [32]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [33]
Ubiquinone biosynthesis protein COQ9, mitochondrial (COQ9) OTM2T1FI COQ9_HUMAN Decreases Expression [11]
Interleukin-33 (IL33) OTT5YWK3 IL33_HUMAN Increases Expression [34]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Phosphorylation [35]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [34]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Secretion [36]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Increases Secretion [37]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [38]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [35]
Protein kinase C beta type (PRKCB) OTYQ0656 KPCB_HUMAN Increases Phosphorylation [37]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Affects Expression [39]
DNA excision repair protein ERCC-1 (ERCC1) OTNPYQHI ERCC1_HUMAN Decreases Expression [10]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [34]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Expression [40]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [37]
Amphiregulin (AREG) OTJFOR67 AREG_HUMAN Increases Expression [37]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [41]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Increases Phosphorylation [37]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Increases Activity [38]
3-mercaptopyruvate sulfurtransferase (MPST) OTCDPH5D THTM_HUMAN Decreases Expression [11]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [42]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [11]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Increases Expression [34]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Expression [34]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [43]
Protein kinase C iota type (PRKCI) OTKBAVT3 KPCI_HUMAN Increases Phosphorylation [37]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Increases Phosphorylation [42]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [44]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Expression [45]
Radiation-inducible immediate-early gene IEX-1 (IER3) OTZJI5FZ IEX1_HUMAN Increases Expression [11]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Activity [33]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [35]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Decreases Expression [46]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [11]
DNA-dependent protein kinase catalytic subunit (PRKDC) OTJVS4EG PRKDC_HUMAN Increases Phosphorylation [47]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Activity [38]
Protein kinase C delta type (PRKCD) OTSEH90E KPCD_HUMAN Increases Phosphorylation [37]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Increases Expression [48]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [45]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Phosphorylation [35]
Transcription factor HES-1 (HES1) OT8P19W2 HES1_HUMAN Increases Activity [49]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [45]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Increases Expression [34]
Extracellular tyrosine-protein kinase PKDCC (PKDCC) OTVXJR26 PKDCC_HUMAN Decreases Expression [11]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Increases Expression [11]
Docking protein 6 (DOK6) OTX55OIF DOK6_HUMAN Decreases Expression [11]
tRNA-splicing endonuclease subunit Sen2 (TSEN2) OT1UWYRI SEN2_HUMAN Decreases Expression [11]
Protein FAN (NSMAF) OTYNVZ23 FAN_HUMAN Decreases Expression [11]
Probable ATP-dependent RNA helicase DDX17 (DDX17) OTXRMMBP DDX17_HUMAN Decreases Expression [11]
F-box/WD repeat-containing protein 5 (FBXW5) OT5TQK3H FBXW5_HUMAN Increases Expression [11]
PRKC apoptosis WT1 regulator protein (PAWR) OTKY7W52 PAWR_HUMAN Decreases Expression [11]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Increases Expression [37]
Homeobox protein HMX1 (HMX1) OT65ZGE0 HMX1_HUMAN Increases Expression [11]
Abl interactor 2 (ABI2) OT8GIIS5 ABI2_HUMAN Decreases Expression [11]
Inhibitor of Bruton tyrosine kinase (IBTK) OTB2GM4G IBTK_HUMAN Decreases Expression [11]
SERTA domain-containing protein 1 (SERTAD1) OTBHKZQP SRTD1_HUMAN Increases Expression [11]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Response To Substance [50]
Phospholipid phosphatase 1 (PLPP1) OT0IIMI5 PLPP1_HUMAN Decreases Response To Substance [50]
DNA polymerase alpha catalytic subunit (POLA1) OT1WXFVY DPOLA_HUMAN Increases Response To Substance [50]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Response To Substance [51]
Collagen alpha-1(VII) chain (COL7A1) OT3MIRZJ CO7A1_HUMAN Decreases Response To Substance [50]
Integrin alpha-E (ITGAE) OT41KCRX ITAE_HUMAN Increases Response To Substance [50]
Nicastrin (NCSTN) OT5QBTA4 NICA_HUMAN Affects Response To Substance [49]
V-type proton ATPase 21 kDa proteolipid subunit c'' (ATP6V0B) OT8GTI1V VATO_HUMAN Increases Response To Substance [50]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Affects Response To Substance [52]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Increases ADR [53]
DNA polymerase epsilon subunit 2 (POLE2) OTAC9V6L DPOE2_HUMAN Increases Response To Substance [50]
Protein DBF4 homolog A (DBF4) OTBL7JHQ DBF4A_HUMAN Increases Response To Substance [50]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Response To Substance [50]
Cell division cycle protein 20 homolog (CDC20) OTCOEZRV CDC20_HUMAN Increases Response To Substance [50]
RNA-binding motif, single-stranded-interacting protein 1 (RBMS1) OTD13PJN RBMS1_HUMAN Decreases Response To Substance [50]
S-phase kinase-associated protein 2 (SKP2) OTD5B41X SKP2_HUMAN Increases Response To Substance [50]
Pre-B-cell leukemia transcription factor-interacting protein 1 (PBXIP1) OTEAAUBY PBIP1_HUMAN Decreases Response To Substance [50]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Response To Substance [54]
DNA mismatch repair protein Mlh1 (MLH1) OTG5XDD8 MLH1_HUMAN Affects Response To Substance [52]
Origin recognition complex subunit 1 (ORC1) OTHWU8IJ ORC1_HUMAN Increases Response To Substance [50]
U6 snRNA-associated Sm-like protein LSm7 (LSM7) OTHZ2XPX LSM7_HUMAN Increases Response To Substance [50]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1) OTJC60Q7 THIL_HUMAN Increases Response To Substance [50]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases Response To Substance [50]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Decreases Response To Substance [50]
Ras-related protein Rab-31 (RAB31) OTMLXQZ0 RAB31_HUMAN Decreases Response To Substance [50]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Decreases Response To Substance [55]
Plasma membrane calcium-transporting ATPase 4 (ATP2B4) OTMWFDAC AT2B4_HUMAN Decreases Response To Substance [50]
E3 ubiquitin-protein ligase CCNB1IP1 (CCNB1IP1) OTOTVMC8 CIP1_HUMAN Increases Response To Substance [50]
Protein FAM50B (FAM50B) OTP3H38A FA50B_HUMAN Increases ADR [56]
DNA fragmentation factor subunit beta (DFFB) OTPBW5N5 DFFB_HUMAN Increases Response To Substance [50]
ATP-binding cassette sub-family B member 6 (ABCB6) OTPGZFES ABCB6_HUMAN Decreases Response To Substance [57]
E3 ubiquitin-protein ligase RNF34 (RNF34) OTQY58LU RNF34_HUMAN Decreases Response To Substance [44]
DNA-directed RNA polymerase III subunit RPC7 (POLR3G) OTU3TGQ9 RPC7_HUMAN Increases Response To Substance [50]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Response To Substance [58]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [27]
Protein NDRG1 (NDRG1) OTVO66BO NDRG1_HUMAN Decreases Response To Substance [59]
Phosphoserine aminotransferase (PSAT1) OTVV1YV9 SERC_HUMAN Increases Response To Substance [50]
Uncharacterized protein C8orf34 (C8ORF34) OTXCTHDG CH034_HUMAN Increases ADR [53]
Small nuclear ribonucleoprotein F (SNRPF) OTZE5W6G RUXF_HUMAN Increases Response To Substance [50]
Adenylate kinase 2, mitochondrial (AK2) OTZG3X2H KAD2_HUMAN Increases Response To Substance [50]
------------------------------------------------------------------------------------
⏷ Show the Full List of 469 DOT(s)
Indication(s) of Oxaliplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [4]
Appendiceal neoplasm N.A. Approved [4]
Cholangiocarcinoma 2C12.10 Approved [4]
Colon adenocarcinoma N.A. Approved [4]
Colorectal cancer 2B91.Z Approved [5]
Colorectal carcinoma N.A. Approved [4]
Endocrine gland neoplasm N.A. Approved [4]
Gallbladder carcinoma N.A. Approved [4]
Metastasis from malignant tumor of colon N.A. Approved [4]
Nasopharyngeal carcinoma 2B6B Approved [4]
Peritoneal neoplasm N.A. Approved [4]
Rectal adenocarcinoma 2B92 Approved [4]
Rectal neoplasm N.A. Approved [4]
Rectum mucinous adenocarcinoma N.A. Approved [4]
Colon cancer 2B90.Z Investigative [4]
Gastric cancer 2B72 Investigative [4]
Oxaliplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [60]
------------------------------------------------------------------------------------
Oxaliplatin Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [61]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [62]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [63]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [64]
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [65]
------------------------------------------------------------------------------------
Oxaliplatin Interacts with 12 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [66]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Metabolism [66]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [66]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Metabolism [66]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [67]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [67]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [67]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [67]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [67]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [67]
Superoxide dismutase 1 (SOD1) DEUTDON SODC_HUMAN Metabolism [67]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [67]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DME(s)
Oxaliplatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Increases ADR [68]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Small Intestine Adenocarcinoma DC1XR8L N. A. Phase 2 [69]
Adenocarcinoma of the Gastroesophageal Junction DCX3992 N. A. Phase 2 [70]
Metastatic Colorectal Cancer DCZ66Q6 N. A. Phase 2 [71]
Colorectal Cancer DCI5H5R N. A. Phase 1 [72]
Unspecified Adult Solid Tumor, Protocol Specific DCIA2YB N. A. Phase 1 [73]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01558869) Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
2 Irinotecan FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6823).
4 Oxaliplatin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
6 Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
7 Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol. 2005 May;67(5):1732-9.
8 In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
9 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
10 Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs. 2001 Oct;12(9):741-51. doi: 10.1097/00001813-200110000-00006.
11 Gene expression profile of colon cancer cell lines treated with SN-38. Chemotherapy. 2010;56(1):17-25. doi: 10.1159/000287353. Epub 2010 Feb 24.
12 UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. 2004 Sep-Oct;24(5A):2893-6.
13 Differential rates of glucuronidation for 7-ethyl-10-hydroxy-camptothecin (SN-38) lactone and carboxylate in human and rat microsomes and recombinant UDP-glucuronosyltransferase isoforms. Drug Metab Dispos. 2005 Jul;33(7):977-83. doi: 10.1124/dmd.104.003491. Epub 2005 Apr 15.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
16 Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
17 Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
18 P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
19 Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
20 Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
21 Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
22 Drug Interactions Flockhart Table
23 Drugs that may have potential CYP2B6 interactions.
24 Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
25 Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996 Aug 15;56(16):3752-7.
26 Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther. 2006 Nov;5(11):1450-6.
27 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
28 A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther. 2006 Oct;319(1):82-104. doi: 10.1124/jpet.106.103606. Epub 2006 Jun 30.
29 Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
30 Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab Dispos. 2002 Apr;30(4):391-6.
31 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 2004 Mar-Apr;24(2A):417-23.
32 Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. J Med Chem. 2011 Dec 22;54(24):8328-42. doi: 10.1021/jm2007326. Epub 2011 Nov 23.
33 Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005 Dec;4(12):2026-36. doi: 10.1158/1535-7163.MCT-05-0262.
34 The PPAR-dependent effect of flavonoid luteolin against damage induced by the chemotherapeutic irinotecan in human intestinal cells. Chem Biol Interact. 2022 Jan 5;351:109712. doi: 10.1016/j.cbi.2021.109712. Epub 2021 Oct 23.
35 Irinotecan induces senescence and apoptosis in colonic cells in vitro. Toxicol Lett. 2012 Oct 2;214(1):1-8. doi: 10.1016/j.toxlet.2012.08.004. Epub 2012 Aug 14.
36 Ursolic and oleanolic acids in combination therapy inhibit migration of colon cancer cells through down-regulation of the uPA/uPAR-dependent MMPs pathway. Chem Biol Interact. 2022 Dec 1;368:110202. doi: 10.1016/j.cbi.2022.110202. Epub 2022 Oct 1.
37 Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol. 2005 Apr;55(4):393-403. doi: 10.1007/s00280-004-0904-0. Epub 2004 Oct 5.
38 Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer. 2008 Jan 29;98(2):335-44. doi: 10.1038/sj.bjc.6604082. Epub 2008 Jan 8.
39 The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. Cancer Sci. 2004 May;95(5):464-8. doi: 10.1111/j.1349-7006.2004.tb03233.x.
40 Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib. Invest New Drugs. 2019 Oct;37(5):948-960. doi: 10.1007/s10637-018-00717-9. Epub 2019 Jan 5.
41 Transcriptional repression of O6-methylguanine DNA methyltransferase gene rendering cells hypersensitive to N,N'-bis(2-chloroethyl)-N-nitrosurea in camptothecin-resistant cells. Mol Pharmacol. 2008 Aug;74(2):517-26. doi: 10.1124/mol.107.043620. Epub 2008 May 20.
42 Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 2005 Oct 1;65(19):8951-60. doi: 10.1158/0008-5472.CAN-05-0961.
43 Decreased translation of p21waf1 mRNA causes attenuated p53 signaling in some p53 wild-type tumors. Cell Cycle. 2012 May 1;11(9):1818-26. doi: 10.4161/cc.20208. Epub 2012 May 1.
44 Exogenous expression of hRFI induces multidrug resistance through escape from apoptosis in colorectal cancer cells. Anticancer Res. 2005 Jul-Aug;25(4):2737-41.
45 Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol Cancer Ther. 2006 Jan;5(1):68-79. doi: 10.1158/1535-7163.MCT-05-0107.
46 The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol. 2005 Jun;131(6):385-94. doi: 10.1007/s00432-004-0664-6. Epub 2005 Mar 8.
47 DNA topoisomerase inhibitor, etoposide, enhances GC-box-dependent promoter activity via Sp1 phosphorylation. Cancer Sci. 2007 Jun;98(6):858-63. doi: 10.1111/j.1349-7006.2007.00476.x. Epub 2007 Apr 18.
48 Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs. 2012 Jun;30(3):1248-56. doi: 10.1007/s10637-010-9626-9. Epub 2011 Jan 11.
49 gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009 Jan 15;69(2):573-82. doi: 10.1158/0008-5472.CAN-08-2088.
50 Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
51 Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. Mol Cancer. 2011 Apr 20;10:44. doi: 10.1186/1476-4598-10-44.
52 Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. Oncol Rep. 2008 Nov;20(5):999-1004.
53 A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer. Pharmacogenomics J. 2013 Oct;13(5):417-22. doi: 10.1038/tpj.2012.24. Epub 2012 Jun 5.
54 Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol. 2003 Feb;61(3):187-96. doi: 10.1023/a:1022554824129.
55 Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007 May 15;67(10):4860-8. doi: 10.1158/0008-5472.CAN-06-3096.
56 Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
57 Expression of ABCB6 is related to resistance to 5-FU, SN-38 and vincristine. Anticancer Res. 2014 Sep;34(9):4767-73.
58 Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol. 2007 Sep;72(3):686-94. doi: 10.1124/mol.107.036889. Epub 2007 May 30.
59 Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. Clin Cancer Res. 2005 May 1;11(9):3296-302. doi: 10.1158/1078-0432.CCR-04-2417.
60 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
61 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
62 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
63 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
64 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
65 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
66 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
67 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
68 Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012 Jun 1;118(11):2828-36. doi: 10.1002/cncr.26614. Epub 2011 Oct 21.
69 ClinicalTrials.gov (NCT00433550) Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
70 ClinicalTrials.gov (NCT00084617) Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
71 ClinicalTrials.gov (NCT04097444) CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
72 ClinicalTrials.gov (NCT00003594) Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
73 ClinicalTrials.gov (NCT00074321) Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors